JP2008546811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546811A5 JP2008546811A5 JP2008518575A JP2008518575A JP2008546811A5 JP 2008546811 A5 JP2008546811 A5 JP 2008546811A5 JP 2008518575 A JP2008518575 A JP 2008518575A JP 2008518575 A JP2008518575 A JP 2008518575A JP 2008546811 A5 JP2008546811 A5 JP 2008546811A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- prevention
- diseases
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 238000011282 treatment Methods 0.000 claims 20
- 230000002265 prevention Effects 0.000 claims 14
- 229940080349 GPR agonist Drugs 0.000 claims 13
- 229940123344 GPR antagonist Drugs 0.000 claims 13
- 210000000056 organ Anatomy 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 10
- 230000032683 aging Effects 0.000 claims 8
- 230000001640 apoptogenic effect Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000015925 Proto-oncogene Mas Human genes 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000009467 reduction Effects 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 201000004384 Alopecia Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 201000001881 impotence Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000014181 Bronchial disease Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000012981 Hank's balanced salt solution Substances 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229920006237 degradable polymer Polymers 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000013020 embryo development Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000002270 ergogenic effect Effects 0.000 claims 1
- 210000004996 female reproductive system Anatomy 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000004995 male reproductive system Anatomy 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000002687 nonaqueous vehicle Substances 0.000 claims 1
- 239000000346 nonvolatile oil Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- -1 research Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000019100 sperm motility Effects 0.000 claims 1
- 230000021595 spermatogenesis Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000037905 systemic hypertension Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502497-8A BRPI0502497A (pt) | 2005-06-28 | 2005-06-28 | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
| PCT/BR2006/000125 WO2007000036A2 (en) | 2005-06-28 | 2006-06-28 | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000248A Division JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008546811A JP2008546811A (ja) | 2008-12-25 |
| JP2008546811A5 true JP2008546811A5 (enExample) | 2009-08-20 |
Family
ID=37595483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518575A Withdrawn JP2008546811A (ja) | 2005-06-28 | 2006-06-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2013000248A Pending JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2017036611A Pending JP2017114901A (ja) | 2005-06-28 | 2017-02-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000248A Pending JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2017036611A Pending JP2017114901A (ja) | 2005-06-28 | 2017-02-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080312129A1 (enExample) |
| EP (1) | EP1904087A2 (enExample) |
| JP (3) | JP2008546811A (enExample) |
| CN (1) | CN101247818A (enExample) |
| BR (1) | BRPI0502497A (enExample) |
| CA (1) | CA2613126A1 (enExample) |
| WO (1) | WO2007000036A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0602366B1 (pt) | 2006-04-26 | 2017-12-12 | Universidade Federal De Minas Gerais | Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications |
| WO2008052295A1 (en) * | 2006-10-30 | 2008-05-08 | Universidade Federal De Minas Gerais | Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products |
| US8575111B2 (en) | 2007-01-26 | 2013-11-05 | Universidade Federal de Minas Garais-UFMG | Pharmaceutical compositions and methods for treating erectile dysfunction |
| BRPI0800585B8 (pt) | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
| EP2163259B1 (en) | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
| DE102009013456A1 (de) * | 2009-03-18 | 2010-09-23 | GÖPFERICH, Achim, Prof. Dr. | Nanopartikel für die Erkennung von Zellen, durch Bindung an G-Protein gekoppelte Rezeptoren |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| EP2819687A4 (en) * | 2012-02-10 | 2015-09-30 | Tarix Pharmaceuticals Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASES |
| US8557958B1 (en) | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
| EP3016670A4 (en) * | 2013-07-03 | 2017-01-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for treating cognitive dysfunction |
| US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
| JP6666899B2 (ja) | 2014-07-21 | 2020-03-18 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法 |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
| EP4371556A1 (en) | 2022-11-15 | 2024-05-22 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| WO1999065531A1 (en) * | 1998-06-18 | 1999-12-23 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
| US6236766B1 (en) * | 1998-09-11 | 2001-05-22 | General Electric Company | Method and apparatus for zooming digital images |
| WO2000020025A2 (en) * | 1998-10-02 | 2000-04-13 | St. Elizabeth's Medical Center, Inc. | Akt compositions for enhancing survival of cells |
| HK1039279A1 (zh) * | 1998-10-22 | 2002-04-19 | Curagen Corporation | 预测和治疗肾病及相关疾病的基因和蛋白质 |
| AU777620B2 (en) * | 1999-04-09 | 2004-10-21 | Jessie L.S. Au | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| EP1194448A1 (en) * | 1999-05-20 | 2002-04-10 | Human Genome Sciences, Inc. | Seven transmembrane receptor genes |
| DE60121146T2 (de) * | 2000-03-29 | 2007-05-31 | Beth Israel Deaconess Medical Center, Inc., Boston | Anti-angiogenic properties of matin and of fragments or variants thereof |
| JP2003532623A (ja) * | 2000-06-30 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法 |
| WO2002052267A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | A method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| BRPI0105509B8 (pt) * | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| WO2003072059A2 (en) * | 2002-02-27 | 2003-09-04 | Wake Forest University | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| WO2006005470A2 (en) * | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) |
| BRPI0503122A (pt) * | 2005-05-30 | 2007-05-02 | Univ Minas Gerais | composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo |
-
2005
- 2005-06-28 BR BRPI0502497-8A patent/BRPI0502497A/pt not_active Application Discontinuation
-
2006
- 2006-06-28 EP EP06741348A patent/EP1904087A2/en not_active Withdrawn
- 2006-06-28 CA CA002613126A patent/CA2613126A1/en not_active Abandoned
- 2006-06-28 WO PCT/BR2006/000125 patent/WO2007000036A2/en not_active Ceased
- 2006-06-28 CN CNA2006800302306A patent/CN101247818A/zh active Pending
- 2006-06-28 US US11/922,949 patent/US20080312129A1/en not_active Abandoned
- 2006-06-28 JP JP2008518575A patent/JP2008546811A/ja not_active Withdrawn
-
2013
- 2013-01-04 JP JP2013000248A patent/JP2013075911A/ja active Pending
-
2017
- 2017-02-28 JP JP2017036611A patent/JP2017114901A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546811A5 (enExample) | ||
| Liu et al. | A self-assembling peptide hydrogel-based drug co-delivery platform to improve tissue repair after ischemia-reperfusion injury | |
| Li et al. | Long-term delivery of alendronate through an injectable tetra-PEG hydrogel to promote osteoporosis therapy | |
| Plotkin et al. | The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack | |
| JP2021063140A (ja) | コラーゲンペプチドに基づく医薬組成物及びデバイス、並びにその製造の方法及び使用 | |
| US20130095167A1 (en) | Customized compositions and uses thereof | |
| CN105658252A (zh) | 用于控制流体移动的可植入网状物 | |
| Bury et al. | The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers | |
| WO2006062962A3 (en) | Materials and methods for treating and managing plaque disease | |
| He et al. | Molecular self-assembly guides the fabrication of peptide nanofiber scaffolds for nerve repair | |
| Nam et al. | Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration | |
| Lim et al. | Biomaterials for enhancing CNS repair | |
| WO2010127254A2 (en) | Thermoresponsive, biodegradable, elastomeric material and uses therefor | |
| US12419936B2 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| Li et al. | A single dose of thermal-sensitive biodegradable hybrid hydrogel promotes functional recovery after spinal cord injury | |
| Chen et al. | In situ construction of ligand nano-network to integrin αvβ3 for angiogenesis inhibition | |
| Ding et al. | Nanosized Silk‐Magnesium Complexes for Tissue Regeneration | |
| Najafi et al. | Integrin receptor-binding nanofibrous peptide hydrogel for combined mesenchymal stem cell therapy and nitric oxide delivery in renal ischemia/reperfusion injury | |
| Zhang et al. | Killing two birds with one stone: A therapeutic copper-loaded bio-patch promoted abdominal wall repair via VEGF pathway | |
| Lv et al. | Injectable multifunctional composite hydrogel as a combination therapy for preventing postsurgical adhesion | |
| US20220332763A1 (en) | Fused polypeptide and use thereof | |
| CN119698289A (zh) | 基于胶原蛋白肽的药物组合物及其用途 | |
| CN101732345A (zh) | 顺铂脊柱肿瘤缓释植入剂及其制备方法 | |
| Applewhite | Controlled Periadventitial Delivery of β-Aminopropionitrile to Promote Arteriovenous Fistula Maturation | |
| Li et al. | Polyethylene Glycol Diacrylate (PEGMA) and Polyvinylpyrrolidone (PVP) Delivering Solifenacine as Super Smooth Coating of Ureteral Stent to Relieve Stent Syndrome: In Vitro and In Vivo Study |